13F Holdings
中文EN

CVRX CVRx, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1235912 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.8%
TTM net income YoY-2.4%
TTM EPS YoY-0.5%
Revenue 3-yr CAGR19.7%
Net income 3-yr CAGR—

Margins

Gross margin86.9%
Operating margin-81.9%
Net margin-88.3%
FCF margin-69.7%
EBITDA margin-80.6%

Returns

ROE-172.2%
ROA-53.5%
ROIC (approx.)-299.0%
Asset turnover0.61x

Leverage & solvency

Liabilities / assets84.2%
Debt / equity4.24x
Current ratio6.80x
Interest coverage-8.03x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$56.65M$51.29M$39.30M$22.47M$13.04M
Cost of revenue$8.31M$8.33M$6.26M$5.00M$3.64M
Gross profit$48.34M$42.96M$33.04M$17.47M$9.40M
R&D expense$11.13M$11.13M$11.63M$9.95M$7.50M
SG&A expense$88.47M$91.32M$64.51M$50.05M$27.86M
Operating income-$51.27M-$59.49M-$43.10M-$42.53M-$25.97M
Interest expense$5.83M$4.40M$1.80M$165,000$2.22M
Pretax income-$53.32M-$59.91M-$41.05M-$41.32M-$42.99M
Income tax-$18,000$55,000$147,000$109,000$91,000
Net income-$53.31M-$59.97M-$41.20M-$41.43M-$43.08M
EBITDA-$50.51M-$58.87M-$42.58M-$42.12M-$25.80M
EPS (basic)-2.04-2.65-1.99-2.02-4.16
EPS (diluted)-2.04-2.65-1.99-2.02-4.16
Weighted avg. shares (diluted)26.08M22.60M20.75M20.53M10.36M
Balance sheet
Cash & equivalents$75.71M$105.93M$90.57M$106.19M$142.07M
Receivables$10.66M$9.27M$7.60M$5.50M$2.56M
Inventory$12.21M$12.11M$10.98M$6.96M$3.88M
Current assets$101.65M$129.81M$112.09M$122.88M$151.10M
PP&E, net$2.24M$2.50M$1.76M$1.70M$1.43M
Total assets$104.79M$133.41M$115.23M$124.94M$152.55M
Current liabilities$13.32M$10.76M$7.86M$8.09M$5.91M
Long-term debt$49.51M$49.27M$29.22M$6.75M$0
Total debt$49.51M$49.27M$29.22M$6.75M$0
Total liabilities$65.47M$62.36M$39.28M$15.76M$6.59M
Shareholders' equity$39.32M$71.06M$75.95M$109.18M$145.96M
Net debt-$26.19M-$56.66M-$61.35M-$99.45M-$142.07M
Shares outstanding26.31M25.32M20.88M20.66M20.40M
Cash flow statement
Operating cash flow-$40.17M-$39.14M-$39.02M-$42.68M-$27.73M
Capital expenditure$580,000$1.36M$591,000$685,000$1.18M
Free cash flow-$40.75M-$40.51M-$39.61M-$43.36M-$28.91M
Investing cash flow-$580,000-$1.36M-$591,000-$685,000-$1.18M
Financing cash flow$10.52M$55.87M$23.98M$7.49M$111.88M
Depreciation & amortization$756,000$619,000$522,000$412,000$168,000
Stock-based compensation$11.05M$19.05M$6.30M$3.89M$1.91M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.